Research Triangle Park, NC-based BioCryst Pharmaceuticals Inc. received a $44 million contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Moreover, the NIH added another $3 million to an existing contract to help the company support the development of completion of parts 1 and 2 of a clinical trial testing galidesivir in Brazil. Additionally, the funds go to support the conduct of a Phase 2 clinical trial evaluating galidesivir in non-hospitalized COVID-19 patients at high risk for developing serious complications of COVID-19. The funding will also help the company conduct a clinical pharmacology trial of the investigational drug to determine appropriate dosing in patients with renal impairment.
What is Galidesivir
An adenosine analog, antiviral drug, galidesivir was developed by BioCryst Pharmaceuticals with funding from NIAID, originally as a treatment for hepatitis C; however, later on it was developed as a possible treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease.
Galidesivir Testing for COVID-19
By April 9, 2020, BioCryst commenced a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of the drug in patients with COVID-19. The trial NCT03891420 is funded by NIAID with trial sites in Brazil. Esper Kallas, MD PhD, University of Sao Paulo, serves as principal investigator.
Esper Kallas, MD PhD, University of Sao Paulo, Brazil